股本结构
单位：万股
| 公告日期 | 2024-08-29 | 2024-04-25 | 2024-02-01 | 2021-03-22 | 2021-03-18 | 2021-03-18 |
|---|---|---|---|---|---|---|
| 证券总股本 | 120.89 | 1450.71 | 1450.11 | 1441.01 | 1441.01 | 954.82 |
| 普通股本 | 120.89 | 1450.71 | 1450.11 | 1441.01 | 1441.01 | 954.82 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-09-03 | 2024-04-24 | 2023-12-31 | 2021-03-18 | 2021-03-01 | 2020-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-08-29 | 120.89 | 未披露 |
更多>>
every 12 shares of the combined company’s common stock outstanding will be combined and reclassified into 1 share of the combined company’s common stock
|
2024-09-03 |
| 2024-04-25 | 1450.71 | 未披露 | 定期报告 | 2024-04-24 |
| 2024-02-01 | 1450.11 | 未披露 |
更多>>
From December 31, 2022 to December 31,2023
Issuance of common stock upon vesting of Restricted Stock Units
|
2023-12-31 |
| 2021-03-22 | 1441.01 | 未披露 | 定期报告 | 2021-03-18 |
| 2021-03-18 | 1441.01 | 未披露 | 定期报告 | 2021-03-01 |
| 2021-03-18 | 954.82 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
|
2020-12-31 |
| 2020-10-28 | 932.15 | 未披露 | 定期报告 | 2020-10-14 |
| 2020-11-02 | 928.56 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock for cash,net of offering costs
|
2020-09-30 |
| 2020-08-05 | 590.53 | 未披露 | 定期报告 | 2020-07-31 |
| 2020-07-22 | 448.19 | 未披露 | 定期报告 | 2020-07-21 |
| 2020-07-14 | 340.34 | 未披露 | 定期报告 | 2020-07-13 |
| 2020-08-05 | 226.76 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
|
2020-06-30 |
| 2020-06-03 | 194.21 | 未披露 |
更多>>
1.Common Stock Offered By the company 348,000 shares
2.The above discussion and table are based on 1,594,070 shares of common stock outstanding as of June 2, 2020
|
2020-06-03 |
| 2020-07-14 | 159.41 | 未披露 | 定期报告 | 2020-05-06 |
| 2019-11-06 | 159.41 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock for cash,net of offering costs
|
2019-09-30 |
| 2019-08-01 | 145.56 | 未披露 |
更多>>
from March 31, 2019 to June 30,2019
Issuance of common stock for cash,net of offering costs
|
2019-06-30 |
| 2019-06-28 | 156.36 | 未披露 | 定期报告 | 2019-06-27 |
| 2019-05-20 | 141.35 | 未披露 | 定期报告 | 2019-05-20 |
| 2019-05-20 | 130.38 | 未披露 | 定期报告 | 2019-05-17 |
| 2019-05-09 | 125.81 | 未披露 | 定期报告 | 2019-05-08 |
| 2019-05-08 | 109.88 | 未披露 |
更多>>
from December 31, 2018 to April 4, 2019
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
On April 3, 2019, ARCA biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Amendment”), to implement an eighteen-for-one reverse split of its common stock (the “Reverse Split”), as previously authorized and approved at a special meeting of the Company’s stockholders on October 18, 2018. The Reverse Split will be effective as of 5:01 p.m. (Eastern Time) on April 3, 2019, and the Company’s common stock will continue trading on the Nasdaq Capital Market on a post-split basis on April 4, 2019.
|
2019-04-04 |
| 2019-02-27 | 1835.51 | 未披露 | 定期报告 | 2019-02-22 |
| 2019-02-27 | 1392.41 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2018-12-31 |
| 2018-11-14 | 1392.41 | 未披露 | 定期报告 | 2018-11-12 |
| 2018-05-08 | 1392.38 | 未披露 |
更多>>
From December 31, 2017 to April 4, 2018
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2018-04-04 |
| 2018-05-08 | 1391.43 | 未披露 |
更多>>
from December 31, 2017 to March 19, 2018
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2018-03-19 |
| 2018-03-22 | 1177.51 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2017-12-31 |
| 2017-11-09 | 1175.10 | 未披露 | 定期报告 | 2017-11-07 |
| 2017-11-09 | 1175.07 | 未披露 |
更多>>
from December 31, 2016 to July 31,2017
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2017-07-31 |
| 2017-08-03 | 1011.66 | 未披露 |
更多>>
From December 31, 2016 to June 30, 2017
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2017-06-30 |
| 2017-05-15 | 924.23 | 未披露 | 定期报告 | 2017-05-11 |
| 2017-04-21 | 918.24 | 未披露 | 定期报告 | 2017-04-10 |
| 2017-05-15 | 917.29 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
|
2017-03-31 |
| 2017-03-21 | 913.09 | 未披露 | 定期报告 | 2017-03-17 |
| 2017-03-21 | 908.24 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Issuance of common stock upon vesting of Restricted Stock Units
|
2016-12-31 |
| 2016-11-14 | 908.24 | 未披露 | 定期报告 | 2016-11-10 |
| 2016-11-14 | 908.07 | 未披露 |
更多>>
From December 31,2015 to September 30, 2016
Issuance of common stock upon vesting of Restricted Stock Units
|
2016-09-30 |
| 2016-04-27 | 906.63 | 未披露 | 定期报告 | 2016-04-12 |
| 2016-05-11 | 905.66 | 未披露 |
更多>>
from December 31, 2015 to March 15, 2016
Issuance of common stock upon vesting of Restricted Stock Units
|
2016-03-15 |
| 2016-03-17 | 905.12 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
Adjustment for fractional shares
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
|
2015-12-31 |
| 2015-11-12 | 905.12 | 未披露 | 定期报告 | 2015-11-10 |
| 2015-11-12 | 904.98 | 未披露 |
更多>>
From December 31, 2014 to September 30, 2015
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
Adjustment for fractional shares
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
|
2015-09-30 |
| 2015-11-12 | 903.14 | 未披露 |
更多>>
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
|
2015-09-04 |
| 2015-08-11 | 6322.00 | 未披露 |
更多>>
from December 31, 2014 to June 30, 2015
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
On June 16, 2015, we issued to the selling stockholders named below an aggregate of 42,021,579 shares of common stock and warrants to purchase an additional 16,808,632 shares of common stock in a private placement.
|
2015-06-30 |
| 2015-05-12 | 2119.84 | 未披露 |
更多>>
from December 31, 2014 to March 17, 2015
Issuance of common stock upon vesting of Restricted Stock Units
|
2015-03-17 |
| 2015-03-19 | 2115.05 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of warrants for cash
Issuance of common stock upon vesting of Restricted Stock Awards
|
2014-12-31 |
| 2014-11-12 | 2115.05 | 未披露 | 定期报告 | 2014-11-10 |
| 2014-11-12 | 2114.05 | 未披露 |
更多>>
from December 31, 2013 to September 30, 2014
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of warrants for cash
Issuance of common stock upon vesting of Restricted Stock Awards
|
2014-09-30 |
| 2014-08-13 | 2101.08 | 未披露 |
更多>>
From December 31, 2013 to May 9, 2014
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon exercise of warrants for cash
|
2014-05-09 |
| 2014-05-13 | 2100.17 | 未披露 |
更多>>
from December 31, 2013 to March 31, 2014
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of warrants for cash
|
2014-03-31 |
| 2014-03-20 | 2097.98 | 未披露 | 定期报告 | 2014-03-17 |
| 2014-03-20 | 1568.56 | 未披露 |
更多>>
From December 31,2012 to December 31,2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
Conversion of preferred stock to common stock, net of conversion costs
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
|
2013-12-31 |
| 2013-11-13 | 1567.56 | 未披露 | 定期报告 | 2013-11-08 |
| 2013-11-13 | 1319.54 | 2.49 |
更多>>
from December 31, 2012 to September 30, 2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
Issuance of Series A convertible preferred stock, net of offering costs
Conversion of preferred stock to common stock
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
|
2013-09-30 |
| 2013-08-13 | 1095.08 | 未披露 | 定期报告 | 2013-08-09 |
| 2013-08-01 | 1036.09 | 5.32 | 定期报告 | 2013-07-30 |
| 2013-08-13 | 1009.62 | 5.59 |
更多>>
from December 31, 2012 to June 30, 2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
Issuance of Series A convertible preferred stock, net of offering costs
Conversion of preferred stock to common stock
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
|
2013-06-30 |
| 2013-05-13 | 318.56 | 未披露 |
更多>>
from December 31,2012 to March 18,2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
|
2013-03-18 |
| 2013-02-01 | 320.00 | 未披露 |
更多>>
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.The reverse stock split reduced the number of shares of ARCA’s issued and outstanding common stock from approximately 19.1 million shares to approximately 3.2 million shares.
|
2013-03-05 |
| 2013-02-11 | 1908.83 | 未披露 | 定期报告 | 2013-02-05 |
| 2012-11-13 | 1544.48 | 未披露 | 定期报告 | 2012-11-09 |
| 2012-11-13 | 1461.96 | 未披露 |
更多>>
from December 31, 2011 to August 10,2012
Issuance of common stock for cash, net of offering costs
|
2012-08-10 |
| 2012-03-27 | 1218.30 | 未披露 |
更多>>
from Dec 31,2010 to Dec 31,2011
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of stock options for cash
|
2011-12-31 |
| 2011-08-15 | 1051.63 | 未披露 | 定期报告 | 2011-08-11 |
| 2011-08-15 | 1051.57 | 未披露 |
更多>>
from December 31, 2010 to June 30, 2011
Issuance of common stock for cash, net of offering costs
|
2011-06-30 |
| 2011-05-16 | 1051.52 | 未披露 | 定期报告 | 2011-05-12 |
| 2010-08-10 | 883.45 | 未披露 | 定期报告 | 2010-08-10 |
| 2010-08-10 | 883.04 | 未披露 |
更多>>
from December 31, 2009 to June 30, 2010
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of stock options for cash
|
2010-06-30 |
| 2010-03-04 | 762.04 | 未披露 |
更多>>
from December 31, 2008 to December 31, 2009
Conversion of preferred stock
Adjustment for fractional shares on common conversion
Conversion of convertible notes and related accrued interest
Merger with Nuvelo, Inc.
Adjustment for fractional shares
Issuance of common stock upon exercise of stock options for cash
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units
|
2009-12-31 |
| 2009-03-27 | 756.74 | 未披露 |
更多>>
On January 27 2009, ARCA biopharma, Inc., formerly known as Nuvelo, Inc., or Nuvelo, completed the merger contemplated by that Agreement and Plan of Merger and Reorganization, dated September 24, 2008, as amended October 28, 2008, by and among Nuvelo, Dawn Acquisition Sub, Inc., a wholly-owned subsidiary of Nuvelo, or Merger Sub, and ARCA biopharma, Inc., or ARCA, a privately held developmental-stage biopharmaceutical company based in Broomfield, Colorado, which merger agreement, as amended, is referred to herein as the Merger Agreement.
|
2009-03-17 |
| 2009-03-27 | 268.70 | 未披露 |
更多>>
from December 31, 2007 to January 28, 2009
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units
On January 23, 2009, Nuvelo’s stockholders approved an amendment to Nuvelo’s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo’s common stock. Pursuant to the approval by the stockholders, Nuvelo’s board of directors approved the reverse stock split at a ratio of 20-to-1. The reverse stock split became effective after the close of the markets on January 27, 2009.
|
2009-01-28 |
| 2008-03-12 | 5350.60 | 未披露 | 定期报告 | 2008-02-29 |
| 2008-03-12 | 5342.15 | 未披露 |
更多>>
from December 31, 2006 to December 31, 2007
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock upon cashless exercise of warrants
|
2007-12-31 |
| 2007-03-01 | 5324.28 | 未披露 | 定期报告 | 2007-01-31 |
| 2007-03-01 | 5315.18 | 未披露 |
更多>>
from December 31, 2005 to December 31, 2006
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock through a public offering in February 2006, net of issuance cost of $7,581
Issuance of common stock under Kingsbridge CEFF
|
2006-12-31 |
| 2006-03-15 | 5165.68 | 未披露 | 定期报告 | 2006-02-28 |
| 2006-03-15 | 4414.95 | 未披露 |
更多>>
from December 31, 2004 to December 31, 2005
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock through a public offering in February 2005, net of issuance cost of $4,865
Issuance of common stock under Kingsbridge CEFF, net of issuance cost of $220
|
2005-12-31 |
| 2005-03-16 | 4200.38 | 未披露 | 定期报告 | 2005-02-28 |
| 2005-03-16 | 3222.87 | 未披露 |
更多>>
from December 31, 2003 to December 31, 2004
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock upon exercise of warrants
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock through a public offering in March 2004, net of issuance cost of $5,308
Issuance of common stock in connection with Dendreon license agreement
|
2004-12-31 |
| 2004-03-12 | 2601.97 | 未披露 | 定期报告 | 2004-02-27 |
| 2004-03-12 | 2562.12 | 未披露 |
更多>>
from December 31, 2002 to February 24, 2004
Issuance of common stock upon exercise of stock options and under Employee Stock Purchase Plan
Issuance of common stock in connection with Variagenics merger
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock through a public offering in October, 2003, net of issuance cost of $1,846
On February 23, 2004, the Company implemented a one-for-three reverse stock split and reduced the number of outstanding shares of common stock accordingly.
|
2004-02-24 |
| 2003-03-31 | 6298.06 | 未披露 |
更多>>
On January 31, 2003, we completed a merger with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts. As a result of the merger, we issued 1.6451 shares of our common stock in exchange for each Variagenics share, for a total of approximately 39.7 million shares of our common stock, at an approximate purchase price of $48.9 million net of estimated transaction costs of $4.3 million. We changed our name to “Nuvelo, Inc.” in the merger.
|
2003-03-14 |
| 2003-03-31 | 2310.07 | 未披露 |
更多>>
from December 31, 2001 to December 31, 2002
Issuance of common stock upon exercise of stock options and under Employee Stock Purchase Plan
Issuance of common stock through PIPE in April, 2002, net of issuance cost of $751
|
2002-12-31 |
| 2002-04-01 | 1937.11 | 未披露 | 定期报告 | 2002-03-15 |
| 2002-04-01 | 1930.77 | 未披露 |
更多>>
from December 31, 2000 to December 31, 2001
Issuance of common stock upon exercise of stock options and under Employee Stock Purchase Plan
Issuance of common stock upon cash exercise of warrants
Issuance of common stock through PIPE in August, 2001, net issuance cost of ($548)
Conversion of line of credit into common stock
|
2001-12-31 |
| 2001-04-02 | 1375.79 | 未披露 | 定期报告 | 2001-03-01 |
| 2001-04-02 | 1372.24 | 未披露 |
更多>>
from December 31, 1999 to December 31, 2000
Issuance of common stock upon exercise of stock options and under ESPP
Issuance of common stock upon cash exercise of warrants
Issuance of common stock upon cashless exercise of warrants
Notes receivable from stockholders repaid by surrendering shares of stock
|
2000-12-31 |
| 2000-03-20 | 1320.46 | 未披露 | 定期报告 | 2000-03-10 |
| 2000-03-20 | 1308.32 | 未披露 |
更多>>
from December 31, 1998 to December 31, 1999
Issuance of common stock upon exercise of stock options and under ESPP
|
1999-12-31 |
| 1999-03-22 | 1298.14 | 未披露 | 定期报告 | 1999-03-05 |
| 1999-03-22 | 1293.06 | 未披露 |
更多>>
from December 31, 1997 to December 31, 1998
Issuance of common stock upon exercise of stock option grants
Issuance of common stock upon exercise of warrants
|
1998-12-31 |
| 1998-03-31 | 1273.40 | 未披露 | 定期报告 | 1998-03-23 |
| 1998-03-31 | 1273.40 | 未披露 |
更多>>
from December 31, 1996 to December 31, 1997
Issuance of Series B preferred stock
Conversion of preferred stock to common stock upon closing of initial public offering
Issuance of common stock for services and equipment
Forfeiture of note receivable from stockholders
Purchase of common stock by Hyseq One Trust
Issuance of common stock to certain officers of the Company
Issuance of common stock upon exercise of stock option grants
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock in connection with the initial public offering, net
Issuance of common stock in a private placement
Repurchase of common stock from the Hyseq One Trust
|
1997-12-31 |
every 12 shares of the combined company’s common stock outstanding will be combined and reclassified into 1 share of the combined company’s common stock
From December 31, 2022 to December 31,2023
Issuance of common stock upon vesting of Restricted Stock Units
From December 31, 2019 to December 31, 2020
Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
From June 30, 2020 to September 30, 2020
Issuance of common stock for cash,net of offering costs
From March 31, 2020 to June 30, 2020
Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
1.Common Stock Offered By the company 348,000 shares
2.The above discussion and table are based on 1,594,070 shares of common stock outstanding as of June 2, 2020
from June 30, 2019 to September 30, 2019
Issuance of common stock for cash,net of offering costs
from March 31, 2019 to June 30,2019
Issuance of common stock for cash,net of offering costs
from December 31, 2018 to April 4, 2019
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
On April 3, 2019, ARCA biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Amendment”), to implement an eighteen-for-one reverse split of its common stock (the “Reverse Split”), as previously authorized and approved at a special meeting of the Company’s stockholders on October 18, 2018. The Reverse Split will be effective as of 5:01 p.m. (Eastern Time) on April 3, 2019, and the Company’s common stock will continue trading on the Nasdaq Capital Market on a post-split basis on April 4, 2019.
from December 31, 2017 to December 31, 2018
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
From December 31, 2017 to April 4, 2018
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2017 to March 19, 2018
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2016 to December 31, 2017
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2016 to July 31,2017
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
From December 31, 2016 to June 30, 2017
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2016 to March 31, 2017
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2015 to December 31, 2016
Issuance of common stock upon vesting of Restricted Stock Units
From December 31,2015 to September 30, 2016
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2015 to March 15, 2016
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2014 to December 31, 2015
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
Adjustment for fractional shares
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
From December 31, 2014 to September 30, 2015
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
Adjustment for fractional shares
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
from December 31, 2014 to June 30, 2015
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon vesting of Restricted Stock Units
On June 16, 2015, we issued to the selling stockholders named below an aggregate of 42,021,579 shares of common stock and warrants to purchase an additional 16,808,632 shares of common stock in a private placement.
from December 31, 2014 to March 17, 2015
Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2013 to December 31, 2014
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of warrants for cash
Issuance of common stock upon vesting of Restricted Stock Awards
from December 31, 2013 to September 30, 2014
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of warrants for cash
Issuance of common stock upon vesting of Restricted Stock Awards
From December 31, 2013 to May 9, 2014
Issuance of common stock for cash,net of offering costs
Issuance of common stock upon exercise of warrants for cash
from December 31, 2013 to March 31, 2014
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of warrants for cash
From December 31,2012 to December 31,2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
Conversion of preferred stock to common stock, net of conversion costs
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
from December 31, 2012 to September 30, 2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
Issuance of Series A convertible preferred stock, net of offering costs
Conversion of preferred stock to common stock
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
from December 31, 2012 to June 30, 2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
Issuance of Series A convertible preferred stock, net of offering costs
Conversion of preferred stock to common stock
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
from December 31,2012 to March 18,2013
Issuance of common stock for cash, net of offering costs
Adjustment for fractional shares
Issuance of common stock upon exercise of warrants for cash
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.The reverse stock split reduced the number of shares of ARCA’s issued and outstanding common stock from approximately 19.1 million shares to approximately 3.2 million shares.
from December 31, 2011 to August 10,2012
Issuance of common stock for cash, net of offering costs
from Dec 31,2010 to Dec 31,2011
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of stock options for cash
from December 31, 2010 to June 30, 2011
Issuance of common stock for cash, net of offering costs
from December 31, 2009 to June 30, 2010
Issuance of common stock for cash, net of offering costs
Issuance of common stock upon exercise of stock options for cash
from December 31, 2008 to December 31, 2009
Conversion of preferred stock
Adjustment for fractional shares on common conversion
Conversion of convertible notes and related accrued interest
Merger with Nuvelo, Inc.
Adjustment for fractional shares
Issuance of common stock upon exercise of stock options for cash
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units
On January 27 2009, ARCA biopharma, Inc., formerly known as Nuvelo, Inc., or Nuvelo, completed the merger contemplated by that Agreement and Plan of Merger and Reorganization, dated September 24, 2008, as amended October 28, 2008, by and among Nuvelo, Dawn Acquisition Sub, Inc., a wholly-owned subsidiary of Nuvelo, or Merger Sub, and ARCA biopharma, Inc., or ARCA, a privately held developmental-stage biopharmaceutical company based in Broomfield, Colorado, which merger agreement, as amended, is referred to herein as the Merger Agreement.
from December 31, 2007 to January 28, 2009
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units
On January 23, 2009, Nuvelo’s stockholders approved an amendment to Nuvelo’s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo’s common stock. Pursuant to the approval by the stockholders, Nuvelo’s board of directors approved the reverse stock split at a ratio of 20-to-1. The reverse stock split became effective after the close of the markets on January 27, 2009.
from December 31, 2006 to December 31, 2007
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock upon cashless exercise of warrants
from December 31, 2005 to December 31, 2006
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock through a public offering in February 2006, net of issuance cost of $7,581
Issuance of common stock under Kingsbridge CEFF
from December 31, 2004 to December 31, 2005
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock through a public offering in February 2005, net of issuance cost of $4,865
Issuance of common stock under Kingsbridge CEFF, net of issuance cost of $220
from December 31, 2003 to December 31, 2004
Issuance of common stock upon exercise of stock options and under employee stock purchase plan
Issuance of common stock upon exercise of warrants
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock through a public offering in March 2004, net of issuance cost of $5,308
Issuance of common stock in connection with Dendreon license agreement
from December 31, 2002 to February 24, 2004
Issuance of common stock upon exercise of stock options and under Employee Stock Purchase Plan
Issuance of common stock in connection with Variagenics merger
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock through a public offering in October, 2003, net of issuance cost of $1,846
On February 23, 2004, the Company implemented a one-for-three reverse stock split and reduced the number of outstanding shares of common stock accordingly.
On January 31, 2003, we completed a merger with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts. As a result of the merger, we issued 1.6451 shares of our common stock in exchange for each Variagenics share, for a total of approximately 39.7 million shares of our common stock, at an approximate purchase price of $48.9 million net of estimated transaction costs of $4.3 million. We changed our name to “Nuvelo, Inc.” in the merger.
from December 31, 2001 to December 31, 2002
Issuance of common stock upon exercise of stock options and under Employee Stock Purchase Plan
Issuance of common stock through PIPE in April, 2002, net of issuance cost of $751
from December 31, 2000 to December 31, 2001
Issuance of common stock upon exercise of stock options and under Employee Stock Purchase Plan
Issuance of common stock upon cash exercise of warrants
Issuance of common stock through PIPE in August, 2001, net issuance cost of ($548)
Conversion of line of credit into common stock
from December 31, 1999 to December 31, 2000
Issuance of common stock upon exercise of stock options and under ESPP
Issuance of common stock upon cash exercise of warrants
Issuance of common stock upon cashless exercise of warrants
Notes receivable from stockholders repaid by surrendering shares of stock
from December 31, 1998 to December 31, 1999
Issuance of common stock upon exercise of stock options and under ESPP
from December 31, 1997 to December 31, 1998
Issuance of common stock upon exercise of stock option grants
Issuance of common stock upon exercise of warrants
from December 31, 1996 to December 31, 1997
Issuance of Series B preferred stock
Conversion of preferred stock to common stock upon closing of initial public offering
Issuance of common stock for services and equipment
Forfeiture of note receivable from stockholders
Purchase of common stock by Hyseq One Trust
Issuance of common stock to certain officers of the Company
Issuance of common stock upon exercise of stock option grants
Issuance of common stock upon cashless exercise of warrants
Issuance of common stock in connection with the initial public offering, net
Issuance of common stock in a private placement
Repurchase of common stock from the Hyseq One Trust